Back to Search
Start Over
Tempting Liver Fibrosis? Long-Term Psoriatic Methotrexate Therapy and Heterozygous α1-Antitrypsin Deficiency.
- Source :
- Dermatology (10188665); Sep2006, Vol. 213 Issue 2, p147-149, 3p, 2 Color Photographs
- Publication Year :
- 2006
-
Abstract
- Background: Dermatologists, or pathologists, occasionally need to decide whether or not to continue methotrexate therapy in a patient with an identifiable risk factor for liver fibrosis, in this instance heterozygous α<subscript>1</subscript>-antitrypsin deficiency. Case Presentation: We relate our experience with an elderly male patient, diagnosed as having α<subscript>1</subscript>-antitrypsin deficiency on a liver biopsy, genotypically confirmed as PiMZ. He had been receiving methotrexate for psoriasis for 17 years with a cumulative dose of 7,200 mg. He was monitored by biochemical profiling and interval (10) liver biopsies. Non-specific changes were seen on liver histology although grade 1 liver fibrosis was seen in his last 2 biopsies. Conclusion: We suggest that methotrexate therapy is relatively safe in patients with heterozygous α<subscript>1</subscript>-antitrypsin deficiency, with no other risk factor. We however advise that the risk of fibrosis should be monitored and that the patient receives appropriate counselling. Copyright © 2006 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Subjects :
- LIVER
FIBROSIS
METHOTREXATE
ALPHA 1-antitrypsin
PSORIASIS
Subjects
Details
- Language :
- English
- ISSN :
- 10188665
- Volume :
- 213
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Dermatology (10188665)
- Publication Type :
- Academic Journal
- Accession number :
- 21871932
- Full Text :
- https://doi.org/10.1159/000093855